Can you maintain weight loss after stopping Wegovy?

Step 1: understand what changes when semaglutide leaves your system

Semaglutide works by activating GLP-1 receptors involved in satiety signalling and gastric emptying. During treatment, appetite is suppressed, fullness arrives sooner, and the brain's reward response to food is dulled. Within weeks of stopping, those effects reverse. Hunger returns (often more intensely than patients expect) because the body's set-point mechanisms haven't changed. The NHS describes this clearly in its patient guidance on semaglutide: the medicine manages appetite while you take it; it doesn't reprogram the biology underneath.

This is worth sitting with for a moment, because the framing matters. Regain after stopping isn't a personal failing. It reflects the same chronic biology that made weight management difficult in the first place. Studies consistently show that metabolic adaptations (including changes to hunger hormones like leptin and ghrelin) persist long after weight is lost, whether through medicine or diet alone. Semaglutide suppresses those signals while it's active. Stopping removes that suppression.

The practical upshot: anyone planning to stop Wegovy should do so with a clear-eyed view of what the body is likely to do, and ideally with a maintenance plan already in place, discussed with their prescriber before the last dose. Understanding whether you can maintain weight loss after Wegovy is a useful starting point when forming that plan.

Step 2: know the actual numbers from trials

The STEP 1 extension study followed participants who stopped semaglutide 2.4mg after 68 weeks and tracked them for a further 52 weeks. On average, they regained around two-thirds of the weight they had lost. Cardiometabolic markers (blood pressure, blood sugar, cholesterol) also returned toward baseline over the same period. This is the most rigorous data available for what discontinuation looks like at scale.

There are important caveats. Trial participants received no structured lifestyle support after stopping; real-world outcomes may differ when someone has genuinely internalised new habits during treatment. A minority of participants in extension data maintained substantially more of their loss than the average, suggesting that lifestyle foundations, not just the medicine, played a role for them. You can read more about realistic weight-loss expectations on Wegovy and how results vary between individuals.

The Wegovy 7.2mg dose, approved by the MHRA in early 2026, produced approximately 20.7% average weight loss over 72 weeks in trials, closer to tirzepatide's results at its highest dose. Whether discontinuation regain follows a similar pattern to the 2.4mg data is not yet fully established, but the biological mechanism is the same.

Step 3: build the factors that slow regain before you stop

The gap between average regain and best-case outcomes is largely explained by what people do during treatment, not just after it. Wegovy creates an unusual window (reduced appetite, fewer cravings, more headroom in the diet) that can be used to build sustainable patterns or simply ridden passively. The evidence suggests the former makes a material difference.

Three areas consistently come up in clinical guidance. First, protein adequacy: maintaining muscle mass during weight loss requires deliberate protein intake, and muscle is the tissue most metabolically active at rest. Second, resistance-based activity: building or preserving muscle through strength training actively works against the metabolic slowdown that accompanies weight loss. Third, sleep and stress management, which directly influence the hunger hormones that resurge after stopping.

NHS England's guidance on weight management injections is explicit that medicines are intended to work alongside, not instead of, sustained lifestyle changes. Stopping without those foundations in place carries a higher regain risk. The timeline for regain after stopping semaglutide is also worth understanding before making any decision.

Step 4: have the stopping conversation with your prescriber, not after the fact

NICE's recommendation (TA875) is that Wegovy is used for a maximum of two years within a specialist weight management service. In practice, this means the stopping point should be a planned clinical decision, not something that happens because a prescription lapses. Your prescriber can review what's been achieved, what risk factors remain, whether continued treatment is appropriate, and what a tapering or transition plan looks like.

Some people switch from Wegovy to tirzepatide (Mounjaro), which works on two receptors rather than one and has shown greater average weight loss in head-to-head trials. Others continue on a lower maintenance dose if their prescriber considers it clinically appropriate. Others stop entirely with a concrete lifestyle plan. None of these paths should be decided in isolation.

If you're thinking about stopping Wegovy after reaching your goal weight, or simply wondering whether long-term treatment is the right call, speaking to a clinician who knows your history is the place to start. At nume, every repeat prescription is reviewed by a GPhC-registered prescriber before it's issued, that review is the right moment to raise the question of what comes next. You can also explore practical strategies for maintaining weight after Wegovy as part of planning ahead.

Current treatment options and eligibility criteria are explained on our free consultation page, a prescriber will look at your full picture before any recommendation is made.